Must be used in combination with PEG-interferon and ribavirin (see separate entries).
- TRADE NAME: Olysio (Janssen)
- INDICATIONS: Hepatitis C
- CLASS: Direct-acting antiviral, Hepatitis C virus NS3/4A protease inhibitor
- HALF-LIFE: 10–13 hours
- FDA APPROVAL DATE: 11/22/2013
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Carbamazepine, Cisapride, Clarithromycin, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Darunavir, Delavirdine, Dexamethasone, Efavirenz, Erythromycin, Etravirine, Fluconazole, Fosamprenavir, Indinavir, Itraconazole, Ketoconazole, Ledipasvir & Sofosbuvir, Lopinavir, Milk Thistle, Nelfinavir, Nevirapine, Oxcarbazepine, Phenobarbital, Phenytoin, Posaconazole, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Tipranavir, Voriconazole - PREGNANCY: simeprevir is pregnancy category C but must not be used in monotherapy
- See adverse reactions attributed to class:
RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
